Alagebrium Mitigates Metabolic Insults in High Carbohydrate and High Fat Diet Fed Wistar Rats
| Autor: | Seba Hassan, Ali Abdelrahman Moustafa, Soad L. Kabil, Nevertyty M. Mahmoud |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Pharmaceutical Science Adipokine lcsh:RS1-441 030204 cardiovascular system & hematology Alagebrium metabolic syndrome lcsh:Pharmacy and materia medica 03 medical and health sciences 0302 clinical medicine Insulin resistance alagebrium Glycation Internal medicine medicine General Pharmacology Toxicology and Pharmaceutics 030304 developmental biology 0303 health sciences medicine.diagnostic_test business.industry advanced glycation end products medicine.disease Metformin Endocrinology Blood pressure Metabolic syndrome business Lipid profile metformin medicine.drug |
| Zdroj: | Pharmaceutical Sciences, Vol 26, Iss 1, Pp 13-24 (2020) |
| ISSN: | 2383-2886 |
| Popis: | Background: Metabolic syndrome (MS) is characterized by sustained hyperglycemia that triggers advanced glycation end products (AGEs) generation. Alagebrium (ALA) is an advanced glycation end products (AGEs) cross-links breaker.Methods: 32 Wistar rats were divided into normal control (NC) group (8 rats) and MS groups (24 rats) received a high carbohydrate high fat diet (HCFD) for 10 weeks. Rats with established MS were equally divided into 3 subgroups remained on HCFD for further 6 weeks: MS control (MSC), ALA treated received 10 mg/kg/day ALA orally and metformin treated (MF) (a reference drug) received 50 mg/kg/day MF orally. The studied parameters were systolic blood pressure (SBP), body and liver weights (BW, LW), LW/BW% ratio, fasting blood glucose (FBG), serum insulin, lipid profile, liver enzymes, serum AGEs, hepatic Interleukin-17 (IL-17), adipokines, pAkt/Akt ratio, and liver histopathology.Results: HCFD elevated SBP, BW, LW and LW/BW% ratio, FBG, serum insulin, and AGEs. It also deteriorated lipid profile and liver enzymes, induced inflammation, insulin resistance and histopathological derangements. ALA ameliorated the elevated SBP, FBG, lipid profile, liver enzymes, mitigated insulin resistance, hepatic IL-17, serum AGEs, modulated adipokines levels and improved liver histopathology. However, MF had better effects than ALA in all studied parameters except AGEs.Conclusion: ALA is protective against dietary-induced MS via ameliorating the inflammatory process and serum AGEs that implicated in MS pathogenesis, which makes it a promising new tool in MS treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|